CORT Positive Sentiment
SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read Key Takeaway: The SYNERGY study investigates the efficacy of nenocorilant combined with nivolumab in patients with advanced solid tumors. Presented by Dr. Omid Hamid at the American Society of Clinical Oncology Annual Meeting, this Phase 1b/2 trial aims to provide insights into this innovative treatment approach. The findings may contribute to new therapeutic strategies in oncology.
Full Press Release Details
Presented : American Society of Clinical Oncology Annual Meeting , 30 May 2026 , Chicago, IL
Presenter : Omid Hamid, MD
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
The post SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies appeared first on Corcept Therapeutics .